LeMaitre Vascular (NASDAQ:LMAT) Raised to Buy at StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Wednesday.

Several other brokerages also recently issued reports on LMAT. JMP Securities raised their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research boosted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $101.07 on Wednesday. The stock’s fifty day moving average price is $90.38 and its two-hundred day moving average price is $83.99. LeMaitre Vascular has a 52-week low of $47.72 and a 52-week high of $103.96. The company has a market cap of $2.27 billion, a price-to-earnings ratio of 55.23, a P/E/G ratio of 2.36 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm’s revenue was up 15.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.33 EPS. On average, equities analysts predict that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors have recently bought and sold shares of the stock. Summit Global Investments lifted its position in LeMaitre Vascular by 2.4% during the third quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock valued at $575,000 after purchasing an additional 146 shares during the last quarter. Shaker Investments LLC OH lifted its position in LeMaitre Vascular by 1.3% during the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock valued at $1,138,000 after purchasing an additional 175 shares during the last quarter. NBC Securities Inc. lifted its position in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 183 shares during the last quarter. GAMMA Investing LLC lifted its position in LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after purchasing an additional 188 shares during the last quarter. Finally, nVerses Capital LLC lifted its holdings in shares of LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 200 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.